We review evidence concerning health-related quality of life (HRQL) following paediatric haemopoietic stem cell transplant. The aims are to determine (1) HRQL compared with population norms; (2) changes in HRQL over time and (3) 
Introduction
The number of haemopoietic stem cell transplants (HSCTs) in childhood has increased in recent years, particularly allogeneic transplants for serious haematological disease (malignant and non-malignant). This has been facilitated by developments in use of alternative donors (unrelated or mismatched related) and stem cell sources (PBSCs or umbilical cord blood, UCB). The commonest indication for allogeneic transplantation in children is leukaemia (62%), followed by non-malignant conditions (36%) and other cancers (2%). 1 Late adverse consequences of HSCT occur both as a result of original treatment for the disease for which HSCT was performed and secondary to toxicity associated with HSCT-conditioning regimens. Additional damage is sustained through the toxic effects of antibiotics, antifungals or immunosuppressive agents used to prevent or treat infections or GVHD. Chronic GVHD may itself cause late treatment-related toxicity. Cardiac, pulmonary, endocrine, renal, neurological, neuropsychological and other late effects have been recorded. Most children experience at least one late physical effect. 2 Published information about late effects typically relates to BMT, but it is anticipated that a similar profile of late effects will be found following PBSC or UCB transplant.
Given the toxicity of treatment, questions have been raised about the quality of life of children during and after HSCT. In a medical context, health-related quality of life (HRQL) is generally acknowledged to be a multidimensional concept. Although there are disagreements about definition of HRQL, 3 a central assumption is that individuals differ in their perceptions and appraisal of the impact of disease on their daily life. 4 Distinctions have been made between generic measures that permit comparisons across conditions regardless of severity or treatment, 5 and disease-specific measures, which focus on functional areas of specific concern and are potentially of greater value for clinicians. 5 HRQL is potentially compromised at all stages of HSCT. Prolonged hospitalization in a protected environment (for 1-3 months) and social isolation (for at least 3 months) are vital to reduce infection, and can potentially disrupt child and family HRQL. 6, 7 Typically, children do not attend school for several months, 8 and this compromises ageappropriate learning and social relationships. 9 Increased dependency on parents, difficulties with resuming age appropriate activities or permanent alterations in developmental trajectory must be anticipated. 10 Disruption to family functioning and relationships are especially likely when family donors are used. 11 In considering the implications of HSCT for their child, families face an arduous initial period and also an uncertain future. There are questions about survival itself, and also long-term HRQL: will the child experience compromised opportunities and experiences? Furthermore, although adverse HRQL consequences of HSCT must be anticipated in the short term, families are keen to have an indication of the likely time course of recovery; that is can a return to normal life be reasonably anticipated? In coping with chronic illness, there are indications that individual resources (for example, optimism) and family relationships (communication quality) contribute to HRQL over and above characteristics of the disease such as severity. 12 Identification of such variables in the context of HSCT would be invaluable for clinic staff, and guide allocation of scarce resources to those most in need. Ultimately, the goal is to identify vulnerable families and provide timely help.
Previous reviews have raised questions regarding HRQL and psychosocial adjustment immediately before and shortly after HSCT. 13, 14 They emphasize the methodological problems inherent in conducting these studies, the range of outcome measures used, and apparent discrepancies between severity of physical problems and survivor or parent ratings of HRQL. Our goal was to contribute further to the literature by focusing specifically on studies using validated measures of HRQL. In addition, we focus on longer-term survivors.
We conducted a systematic literature search of the empirical evidence to determine (1) HRQL compared with population norms; (2) changes in HRQL over time and (3) relations between pre-transplant variables (disease, individual and family resources) and HRQL.
Method
Recommended review methods were employed 15 to ensure a systematic literature search. Five databases (OVID Medline (1966-January week 5, 2008), CINAHL, Psychinfo (1990-February week 1, 2008, British Nursing Index (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) and Journals@OvidFulltext (7 February 2008) ) were searched using Boolean logic with the following terms: stem cell transplant, BMT, child, childhood, children, adolescent, paediatric, pediatric survivor, cancer, quality of life, HRQL, behavior, behaviour, psychosocial, psychological, adjustment. Text word and thesaurus searches were used to minimize chances of missing relevant articles. Identified articles were searched for additional references. Eligibility criteria are shown in Table 1 .
Articles that did not meet eligibility criteria were identified from abstracts and disregarded. Full articles were obtained for remaining papers. Information was extracted from identified articles and coded using a standard review pro-forma (Table 2 ). All papers were independently reviewed (SC and CE). Discrepancies in coding were resolved through discussion.
Results

Study characteristics
A total of 15 eligible articles were identified that included 12 separate cohorts. Information was reviewed collectively in the three cases where articles were based on the same sample. We refer to the article most relevant to psychosocial outcomes for the purpose of this review. Studies were conducted in the US, 7, [16] [17] [18] [19] [20] [21] Sweden, [22] [23] [24] Canada, 25 Netherlands, 26 Spain, 27 Austria 28 and France. 29 All but three 21, 28, 29 were single centre studies. In five studies, the primary aim involved comparison of outcomes with population norms, healthy controls or other groups of sick children, 22, 24, 26, 27, 29 seven described changes in HRQL over time and pre-transplant predictors of HRQL. 7, [16] [17] [18] 21, 25, 28 Sample size ranged from 22 26 to 160 21 and involved 988 children. Age at assessment was 7-32 years for crosssectional studies, and 19 months (pre-) to 23 years (post transplant) for longitudinal research. Two studies (combined N ¼ 200), included detailed information about ethnic group. 16, 17 Of these, 85% were Caucasian, 7.5% Black African Caribbean or Jamaican, 4.5% Hispanic, 0.5% Asian and 2.5% described as other or mixed background.
The most common indication for transplant was malignant haematological disorder (leukaemias and myelodysplastic syndrome; n ¼ 764), followed by lymphomas, solid tumours (Ewing's sarcoma, neuroblastoma) and nonmalignant haematological disorders. 18, 21, 27 Three other studies 22, 28, 26 included allogeneic patients only and one included only autologous patients. 24 Treatment involved BMT for six cohorts, 7, 18, [24] [25] [26] [27] BMT or PBSC transplant for two 22, 28 and SCT, not further specified, in four. 16, 17, 21, 29 One or more standardized measure of HRQL (Table 3 ) was used in eight studies, 18, 21, 22, [25] [26] [27] [28] [29] but these included 12 different measures. Six generic and five cancer-specific measures were used. BMT-specific HRQL measures were used in four studies. 18, 26, 27, 21 Informal measures of HRQL were also employed. Formal measures of behavioural and social functioning, cognitive function and IQ, individual Barrera et al. 25 Phipps and Mulhern 7 Simms et al. 17 Kupst et al.
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Vineland Adaptive Behaviour Scales 45 Generic Barrera et al. 25 Kupst et al.
The Youth Self-Report 46 
Generic
Simms et al.
17
Physical activity Lansky and Karnofsky Scales 47, 48 Cancer specific Forinder et al.
22,23
Symptoms Disease or treatment-related somatic complaints 49 Cancer specific Arvidson et al. and personality characteristics, emotional functioning, symptoms and physical activity were identified in addition to HRQL. Formal assessments of parental anxiety, 25 depression, 25 HRQL, 21 family environment 7 and adaptability and cohesiveness 25 were also reported. Both child and parent proxy ratings were obtained in seven studies. 7, [16] [17] [18] 24, 28, 29 Information was also obtained from teachers 24 and from physicians. 28 In five studies, only parent report 21, 25 or self-reports were included. 22, 26, 27 Research findings HRQL compared with population norms. HRQL, 22, 26, 27, 29 behavioural adjustment, 24 physical activity, 22 somatic symptoms, 24 self-esteem and self-perception 22, 24 and coping 26 were described. Data were compared with population norms, 22, 24, 26 healthy controls 27 or non-HSCT childhood cancer survivors, 29 and are summarized in Table 4 . Pain, 22 compromised general 22 and physical health, 29 poor self-esteem, 22 problem behaviour and lower school competence, 24 concerns about school, work or physical appearance 27 and impaired functioning at work 26 were reported. Survivors were no more likely than healthy controls to report somatic symptoms 24 but were at greater risk of medical adverse effects. 29 Although HSCT survivors reported their HRQL to be comparable with or better than population norms, 22, 24, 26, 27, 29 parents and teachers rated their child's HRQL to be worse than US norms. 24 Changes in HRQL over time. Changes in HRQL or both HRQL and behavioural adjustment were examined before, and up to 6 18,25 or 12 months post-HSCT. 21, 28 Assessments of behavioural and psychosocial or cognitive functioning before HSCT and 6 and 12 months post-BMT, 7 up to 2 16 or 3 years post transplant 17 were also reported (Table 5) . Pre-transplant. Although cognitive functioning and behaviour were within normal ranges pre-transplant, 16, 17, 25 Phipps et al. 18 reported that 'children enter the hospital with an already heightened level of distress (somatic symptoms and mood disturbance, and low levels of activity) that increased dramatically during conditioning, reaching a peak 1 week following transplant' (p 425).
Post transplant (4-12 months). HRQL improved from a very low base over a period of 4-12 months post transplant, 18, 21, 25, 28 with behavioural, cognitive and social functioning returning to normal ranges by 3 years post transplant. 7, 16, 17 Relations between pre-BMT variables and psychological outcome. Demographic variables. Younger children (o6 years) showed less somatic distress, and better HRQL than older children, 19, 21 but those o3 years were at greater risk for later cognitive problems. 17 In contrast, no associations between age at transplant 16, 22, 24, 25 or gender 16, 18 and HRQL were reported. Lower socio-economic status (SES) was associated with poorer HRQL between 3 and 6 months post transplant, 18 lower IQ 7, 16 and social competence 7 at least 1-year post transplant.
Disease-related variables. Pre-transplant symptoms were not related to HRQL or behaviour 6 months 25 or 1-year post transplant. 28 Outcomes were not associated with primary disease, 22 but more intensive treatment (prophylactic central nervous system (CNS) irradiation, treatment of CNS leukaemia/lymphoma or TBI during transplant) was associated with poorer child behaviour and social competence. 24 Children undergoing autologous transplant showed an earlier improvement in mood and better HRQL 6 months post-BMT compared with matched or mismatched allogeneic transplant. 18 Recipients of unrelated donor transplants showed greatest decline in functioning at 3 months post transplant. 21 Another study reported no associations between transplant type and HRQL. 27 Symptom severity and late effects (including GVHD) were associated with lower HRQL post transplant, 22, 25 and those who died within the first year showed lower HRQL post transplant than survivors. 21 Family variables. Family conflict pre-BMT correlated with problem behaviour pre-and post-BMT. 7 In contrast, pre-BMT family expressiveness and cohesion were associated with fewer problem behaviours and better selfconcept and social competence post-BMT. 7, 25 Mothers' anxiety and depression post-HSCT was associated with worse reports of child HRQL but not behaviour. 25 Individual child variables. Worry, compromised emotional functioning, poor communication 28 pre-transplant and during the acute transplant phase have all been linked to poorer HRQL post-BMT. Cognitive, behavioural and social functioning pre-transplant have been associated with cognitive and psychosocial functioning post transplant. 16 
Discussion
Our findings suggest that HRQL improves over a 4-12 months period post transplant. Although HRQL is within baseline range within 1-year post transplant, there is accumulating evidence that pre-transplant baseline is seriously compromised. Predictors of longer-term HRQL include more intensive treatment, pre-HSCT family functioning and child cognitive, behavioural and social functioning.
Better HRQL would be expected following autologous transplant as this avoids the risk and consequences of GVHD, and is associated with less severe and prolonged immune suppression. This has been found for adult patients 62 and children, 18 with poorer HRQL at 3 months post transplant reported for unrelated allogeneic recipients. 21 No differences between allogeneic or autologous survivors were foundX3 years post-HSCT, 27 suggesting any effects may be limited to the short term. However, it should be noted that 73% of 98 survivors received allogeneic transplant. In general, published studies lack sufficient power to detect any differences in HRQL between survivors of autologous or allogeneic transplant.
The results suggest there may be value in further attempts to identify specific family variables associated with HRQL following HSCT. 7, 18, 25 However, a very limited range of variables has been investigated especially compared with those identified as potentially relevant when considering functioning of adult patients post-HSCT. 63 In the same article, Blume and Amylon 63 emphasize the importance of assessing the child's school and social 
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Single center, US Pre and 1-2 yrs post-autologous history, and also the family environment and resources. In that social and family functioning may be more responsive to change than disease variables, family-based interventions may be useful when trying to improve child and family HRQL. However, it must be acknowledged that evidence for the efficacy of family interventions is limited. Psychosocial support (n ¼ 55) before and during HSCT over and above standard care (n ¼ 98) made no difference to psychological outcomes. 16 However, there was a low prevalence of behavioural or social problems throughout the study, and no information about the type of intervention offered.
Our conclusions are limited by the modest number of research studies addressing the question of HRQL in HSCT survivors. As HSCT is used increasingly, more information is needed regarding longer-term medical and psychosocial outcomes to help prepare families for realistic futures. Answers to these questions will only be achieved by addressing methodological problems characteristic of current work.
These include, first, limitations with measures. Generic HRQL measures are typically used to make comparisons between survivor HRQL and population norms. However, population norms are not always available, 25 may not cover the appropriate age range 24 or be culturally appropriate. 22 Disease-specific measures are invaluable if the goal involves detailing the impact of disease or treatment. Currently two HSCT-specific HRQL measures for children have been described. The BASES 39,40 is a child BMT-specific measure but sensitive primarily to issues around transplant. The Disease-Specific Impairment Inventory (DSII)-HSCT is suitable for children 5-18 years and includes three subscales (worry, hassles and body image). 10 It has potential as a disease-specific measure for work with long-term survivors. Availability of such measures will facilitate comparisons across studies in the future. For adult survivors of HSCT during childhood the Functional Assessment of Cancer Therapy (FACT) generic CORE and BMT-specific measures are available. 41 Future assessments of HRQL following HSCT should employ standardized measures with good psychometric properties, which address domains of HRQL relevant to the population, include age appropriate versions, and enable comparisons to be made with culturally appropriate population norms.
Second, there is the issue of research design. Nine studies involving seven separate cohorts employed a longitudinal design to explore changes over time rather than make comparisons between survivors and other groups. Although potentially the more valuable approach, the high morbidity and mortality associated with HSCT, and resulting attrition, means that the results of current research may be less conclusive than might be hoped.
Third, statistical power is typically not stated or insufficient to detect significance, and where results are significant information about effect sizes is often lacking. Furthermore, heterogeneity of methodological quality limits the comparability of findings, so that meta-analyses or comparable procedures cannot be used.
Fourth, all but three studies recruited children from a single treatment centre. Provision of care can differ between centres. 18 Furthermore, most large paediatric transplant centres offer psychosocial care. Results involving patients recruited from these centres may therefore not be generalizable to smaller centres with fewer resources. Future attempts to recruit more ethnically diverse samples would allow for examination of ethnicity as an individual difference variable and improve the generalizability of findings. Fifth, evaluation of HRQL is dependent on respondent, 23, 24 with parents typically reporting more compromised HRQL than children themselves. This wellestablished finding has led to recommendations that children's own assessments be obtained wherever possible. 10, 64, 65 The best parent-child agreement was when HRQL was poor 10 days after transplant. 28 This is a useful finding as it suggests parents may provide a good proxy during the acute treatment phase, when the child may be least willing or able to respond himself.
Efforts to improve methodological rigour of future research are essential, but we must acknowledge the difficulties implicit in this work. In addition to issues of research design, availability of suitable outcome measures and differences between parents and children, evaluation of the implications of HSCT is necessarily confounded by underlying differences in presenting condition or type of transplant. Of special note, Barrera et al. 66 reported that on transplant, HRQL was worse for children treated for ALL or neuroblastoma, whereas those treated for solid tumour or other haematological conditions had HRQL scores nearer the general population. Adolescents also showed poorer HRQL on transplant compared with children. Discussion of change in HRQL over time needs to take into account these differences in baseline HRQL characteristic of presenting disease.
Conclusion
HRQL is severely compromised during and immediately after transplant, 18 but for children and their families, questions about long-term HRQL are invaluable to inform decisions about future education and health care. Clinicians report discussing HRQL issues with patients and 'most HSCT physicians consider providing HRQL data as part of their responsibility to inform patients about the process and risks of treatment' (p. 2198). 67 Despite this, few interventions have addressed issues of HRQL in these patients. Barriers to measuring HRQL in clinic, including perceived burdens on time and difficulty in understanding change scores, need to be addressed. HRQL is potentially compromised in the longer term. Routine evaluation of HRQL needs to be integral part of follow-up after childhood cancer including HSCT. 
